Artificial Intelligence and Robotics in Interventional Cardiology: Preparing for a Transformative Future

Cardiovascular Disease (CVD) remains the leading cause of death worldwide, despite significant advances in pharmacotherapy and interventional techniques. The emergence of Artificial Intelligence (AI) and robotics represents a transformative leap forward in addressing persistent challenges in interventional cardiology, including operator variability, procedural complexity, and limited access in underserved regions. AI enables real-time data interpretation, lesion assessment, and predictive modelling, while robotic systems enhance precision, reduce operator fatigue, and facilitate remote intervention. Together, these technologies are reshaping the interventional landscape with the promise of safer, more efficient, and more personalized care.

This article reviews the current state of AI and robotic integration in leading cardiovascular centres across the globe, highlights patient and physician benefits, and outlines the critical institutional, educational, and policy preparations required to support responsible adoption. Special emphasis is given to the Indonesian experience at Bethsaida Hospital, which has become a national pioneer in using AI to power its Whole Food Plant-Based Diet (WFPBD) program. Bethsaida has reversed chronic diseases and improved outcomes using scalable digital solutions that leverage AI-driven education, metabolic profiling, and patient engagement tools.

Now, under the leadership of Prof. Dasaad Mulijono (DM), Bethsaida is expanding its technological capabilities into robotic-assisted and AI-guided interventional cardiology, setting a precedent in Southeast Asia for integrative, precision-driven cardiovascular care. This work examines the promise of these technologies and the systemic shifts necessary to ensure they enhance rather than replace the human touch in healing.

CVD remains the leading cause of morbidity and mortality globally, accounting for nearly 18 million deaths each year, according to the World Health Organization [1-3]. Despite decades of progress in pharmacologic therapies, imaging technologies, and catheter-based interventions, significant challenges persist, particularly in procedural precision, operator variability, radiation exposure, access to specialized care, and rising healthcare costs.

Interventional cardiology, with its rapid evolution from balloon angioplasty to drug-eluting stents and imaging-guided Percutaneous Coronary Interventions (PCI), now faces its next frontier: integrating AI and robotics. These technologies offer more than incremental improvements-they represent a paradigm shift in how cardiovascular disease is diagnosed, treated, and monitored.

AI enables real-time data analysis, predictive modelling, automated lesion assessment, and clinical decision support that can guide interventional strategies based on vast datasets and pattern recognition beyond human capability. Concurrently, robotic systems provide ultra-precise control of interventional tools, reduce operator fatigue and radiation exposure, and even open the possibility for remote procedures, extending expert care to regions with limited access [4-12].

This transformation is already underway. Leading institutions in the United States, Europe, and Asia are piloting AI-guided angiography interpretation, robotic-assisted PCI, and machine learning models for personalized patient risk profiling. Importantly, integrating AI is not limited to acute interventions but also includes reshaping chronic disease management.

Bethsaida Hospital, Indonesia, for instance, has successfully integrated AI into its WFPBD program to support lifestyle-based cardiac care. AI has enhanced patient engagement and clinical outcomes through personalized education, biometric tracking, and real-time compliance monitoring. Building on this foundation, Bethsaida is preparing to expand its AI applications into the interventional cardiology suite under the leadership of Prof. DM, aiming to become a regional leader in precision and digitally integrated cardiovascular care.

This article reviews the current state of AI and robotics in interventional cardiology, outlines the benefits for patients and physicians, examines the readiness required by hospitals, and discusses future directions, including ethical considerations, reimbursement, and workforce transformation.

Robotic PCI

Platforms like CorPath GRX (Corindus, USA) enable cardiologists to remotely control PCI tools with robotic precision [13-15]. Initial success in tele-stenting suggests possibilities for expanding access to rural and underserved populations.

AI-Driven decision support

Institutions like the Cleveland Clinic [14] and Mount Sinai [16] have adopted AI models to:

• Interpret coronary angiograms
• Predict procedural risks
• Optimize stent sizing and placement
• Reduce radiation exposure and contrast volume

Integrated imaging and AI at imperial college london

Studies are underway to integrate AI with Intravascular Ultrasound (IVUS), Optical Coherence Tomography (OCT), and Fractional Flow Reserve (FFR) data to guide intervention strategies and improve long-term outcomes [17,18].

Benefits to patients:

• Improved Accuracy: Robotic control reduces human error and enhances procedural precision.
• Lower Risk Profiles: AI anticipates complications and guides interventions based on predictive analytics.
• Reduced Radiation and Contrast Load: Automation helps optimize exposure, minimizing the risk of nephropathy and other complications.
• Access to Expertise: Robotic systems enable remote procedures in geographically isolated areas, thereby democratizing access to care.

Benefits to cardiologists:

• Physical Protection: Operating remotely minimizes radiation and orthopaedic strain, increasing career longevity.
• Cognitive Augmentation: AI assists in complex decision-making, enhancing operator confidence and outcomes.
• Skill Democratization: Robotic systems can flatten learning curves and standardize complex procedures across diverse operators.
• Expanded Role: Cardiologists will evolve into hybrid clinicians who combine procedural expertise with digital literacy.

Workforce displacement or evolution?

One of the most frequently voiced concerns regarding the rise of AI and robotics in medicine is the potential displacement of healthcare workers, particularly physicians. However, such fears are overstated mainly in the realm of interventional cardiology. AI and robotic systems are augmentative, not substitutive. They enhance the clinician’s capacity to perform with greater precision, safety, and efficiency-but they do not possess the intuition, adaptability, and empathetic communication required during high-stakes procedures or complex clinical scenarios.

That said, the role of the interventional cardiologist is inevitably evolving. Routine, repetitive, and high-volume tasks-such as basic angiographic measurements, stent sizing, and even aspects of intraprocedural navigation-are increasingly automated or guided by algorithms. As these technologies mature, cardiologists must adapt by developing hybrid competencies that combine deep clinical knowledge with digital literacy, AI fluency, and systems thinking (Figure 1).

Figure 1: Using Artificial Intelligence and robotics in interventional cardiology.

Furthermore, new career pathways may emerge. Cardiologists proficient in data interpretation, procedural analytics, and algorithm refinement may assume leadership roles in digital transformation, clinical validation of AI tools, or even in designing AI-guided protocols. On the other hand, clinicians who resist engaging with these technologies may find their relevance and effectiveness diminish over time.

To ensure future readiness, medical education and continuing professional development must evolve accordingly, incorporating modules on medical informatics, AI ethics, and collaborative workflows with engineers and AI systems.

Hospital readiness

The successful adoption of AI and robotics in interventional cardiology hinges on the availability of technology and the institutional ecosystem that supports it. Hospitals must proactively prepare for this shift through tangible and intangible investments.

Key areas of institutional readiness include:

• Robotic Platforms & Infrastructure: Cath labs must be retrofitted or purpose-built to house robotic systems, ensure seamless integration with imaging and hemodynamic platforms, and support remote operation capabilities.
• Staff Upskilling: Interventional teams-including physicians, nurses, and technologists—require structured training in robotic workflows, AI interfaces, and failure management protocols.
• Cross-disciplinary Collaboration: AI deployment thrives in environments where clinicians work closely with engineers, data scientists, and software developers to fine-tune algorithms and ensure clinical relevance and safety.
• Data Security & Governance: As AI systems depend on vast and sensitive health data, hospitals must prioritize cybersecurity infrastructure, real-time analytics pipelines, and compliance with data privacy regulations like the Health Insurance Portability and Accountability Act (HIPAA) or the General Data Protection Regulation (GDPR).
• Change Management & Culture: Perhaps most critically, hospitals must foster a culture of innovation, continuous learning, and openness to technological evolution. Resistance to change, often cultural rather than technical, can significantly delay adoption and diminish impact.

Institutions that adapt early will likely gain strategic advantages, such as improved clinical outcomes, enhanced operational efficiency, stronger recruitment appeal, and leadership positioning in regional or international cardiovascular care.

Insurance and reimbursement implications

Adopting AI and robotic technology presents a significant financial challenge, particularly for resource-limited healthcare systems. The high upfront costs of robotic platforms, ongoing maintenance, and training must be weighed against the long-term economic and clinical value they deliver.

However, growing evidence suggests that these technologies may be cost-effective in the long run. Studies report [19-22]:

• Reduced complication rates due to increased precision
• Shorter hospital stays and ICU utilization
• Lower readmission rates, particularly in high-risk and complex cases
• Improved procedural standardization, leading to fewer errors and inefficiencies

In countries like the United States, robotic PCI is increasingly covered under standard reimbursement codes in selected hospitals, mainly when supported by documented clinical outcomes. Meanwhile, value-based healthcare frameworks, which reward outcomes over volume, are particularly conducive to high-tech integration, as they align incentives with improved patient care rather than procedure counts.

To ensure equitable access and sustainable adoption, policymakers, insurers, and hospital administrators must collaborate to:

• Develop adaptive reimbursement models that reflect the actual value of innovation
• Establish guidelines for appropriate use, based on clinical indications and cost-benefit analysis
• Encourage pilot programs and registries to collect real-world evidence for AI and robotic interventions
• Explore public-private partnerships to co-fund the digital transformation of cardiovascular care

AI and robotics represent the next frontier in interventional cardiology, offering unprecedented precision, safety, and reach. While these technologies will not replace physicians, they will fundamentally redefine the skills, workflows, and systems required to deliver the highest standards of cardiovascular care. The successful integration of these tools demands thoughtful preparation-not only through financial investment in robotic platforms and digital infrastructure, but also through the upskilling of clinical teams, robust data governance, and the development of adaptive regulatory and reimbursement policies.

Bethsaida Hospital in Indonesia has already demonstrated national leadership in this arena. As the first hospital in the country to integrate artificial intelligence into a structured clinical program, Bethsaida’s WFPBD initiative utilizes AI to personalize dietary education, monitor metabolic improvements, interpret laboratory data, and support patient compliance in real time. This innovative use of technology has proven effective in reversing chronic diseases such as diabetes and coronary artery disease, while empowering patients to participate actively in their recovery.

Building on this foundation, Bethsaida is now poised to become the first hospital in Indonesia to adopt robotic-assisted and AI-guided strategies within its interventional cardiology program. Under the leadership of Prof. DM, this next phase will integrate precision robotics, predictive analytics, and remote interventional capabilities into routine clinical practice, setting a new benchmark for heart centres in Southeast Asia.

By preparing thoughtfully and collaboratively, we can ensure that AI and robotics enhance, rather than complicate, the mission of interventional cardiology: saving lives with compassion, accuracy, and equity. The future of cardiovascular care is more intelligent and human-centred than ever before.

D.M.; Conceptualization, writing, review, and editing.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article.

Conflict of Interest

The authors declare no conflict of interest.

1. Gaidai O, Cao Y, Loginov S. Global Cardiovascular Diseases Death Rate Prediction. Curr Probl Cardiol. 2023 May;48(5):101622. doi: 10.1016/j.cpcardiol.2023.101622. Epub 2023 Jan 29. PMID: 36724816.
2. Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Goh R, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. 2024 Sep 13:zwae281. doi: 10.1093/eurjpc/zwae281. Epub ahead of print. PMID: 39270739.
3. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, et al. GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010. Erratum in: J Am Coll Cardiol. 2021 Apr 20;77(15):1958-1959. doi: 10.1016/j.jacc.2021.02.039. PMID: 33309175; PMCID: PMC7755038.
4. Khelimskii D, Badoyan A, Krymcov O, Baranov A, Manukian S, et al. AI in interventional cardiology: Innovations and challenges. Heliyon. 2024 Aug 26;10(17):e36691. doi: 10.1016/j.heliyon.2024.e36691. PMID: 39281582; PMCID: PMC11402142.
5. Göçer H, Durukan AB. The use of artificial intelligence in interventional cardiology. Turk Gogus Kalp Damar Cerrahisi Derg. 2023 Jul 27;31(3):420-421. doi: 10.5606/tgkdc.dergisi.2023.24791. PMID: 37664782; PMCID: PMC10472472.
6. Subhan S, Malik J, Haq AU, Qadeer MS, Zaidi SMJ, et al. Role of Artificial Intelligence and Machine Learning in Interventional Cardiology. Curr Probl Cardiol. 2023 Jul;48(7):101698. doi: 10.1016/j.cpcardiol.2023.101698. Epub 2023 Mar 14. PMID: 36921654.
7. Sardar P, Abbott JD, Kundu A, Aronow HD, Granada JF, et al. Impact of Artificial Intelligence on Interventional Cardiology: From Decision-Making Aid to Advanced Interventional Procedure Assistance. JACC Cardiovasc Interv. 2019 Jul 22;12(14):1293-1303. doi: 10.1016/j.jcin.2019.04.048. Erratum in: JACC Cardiovasc Interv. 2019 Aug 26;12(16):1634. doi: 10.1016/j.jcin.2019.07.037. PMID: 31320024.
8. Rudnicka Z, Pręgowska A, Glądys K, Perkins M, Proniewska K. Advancements in artificial intelligence-driven techniques for interventional cardiology. Cardiol J. 2024;31(2):321-341. doi: 10.5603/cj.98650. Epub 2024 Jan 22. PMID: 38247435; PMCID: PMC11076027.
9. Itelman E, Witberg G, Kornowski R. AI-Assisted Clinical Decision Making in Interventional Cardiology: The Potential of Commercially Available Large Language Models. JACC Cardiovasc Interv. 2024 Aug 12;17(15):1858-1860. doi: 10.1016/j.jcin.2024.06.013. PMID: 39142763.
10. Aminorroaya A, Biswas D, Pedroso AF, Khera R. Harnessing Artificial Intelligence for Innovation in Interventional Cardiovascular Care. J Soc Cardiovasc Angiogr Interv. 2025 Mar 18;4(3Part B):102562. doi: 10.1016/j.jscai.2025.102562. PMID: 40230673; PMCID: PMC11993883.
11. Alsharqi M, Edelman ER. Artificial Intelligence in Cardiovascular Imaging and Interventional Cardiology: Emerging Trends and Clinical Implications. J Soc Cardiovasc Angiogr Interv. 2025 Mar 18;4(3Part B):102558. doi: 10.1016/j.jscai.2024.102558. PMID: 40230671; PMCID: PMC11993891.
12. Chandramohan N, Hinton J, O'Kane P, Johnson TW. Artificial Intelligence for the Interventional Cardiologist: Powering and Enabling OCT Image Interpretation. Interv Cardiol. 2024 Mar 11;19:e03. doi: 10.15420/icr.2023.13. PMID: 38532946; PMCID: PMC10964291.
13. De Silva K, Myat A, Strange J, Weisz G. Iterative Improvement and Marginal Gains in Coronary Revascularisation: Is Robot-assisted Percutaneous Coronary Intervention the New Hope? Interv Cardiol. 2020 Dec 16;15:e18. doi: 10.15420/icr.2020.24. PMID: 33376506; PMCID: PMC7756352.
14. Young L, Khatri J. Robotic Percutaneous Coronary Intervention: The Good, the Bad, and What is to Come. US Cardiol. 2022 Jan 26;16:e02. doi: 10.15420/usc.2020.28R1. PMID: 39600848; PMCID: PMC11588183.
15. George JC, Varghese V, Madder RD. Robot-Assisted Cardiovascular Interventions. J Soc Cardiovasc Angiogr Interv. 2025 Mar 18;4(3Part B):102568. doi: 10.1016/j.jscai.2025.102568. PMID: 40230678; PMCID: PMC11993876.
16. Moreno PR, Stone GW, Gonzalez-Lengua CA, Puskas JD. The Hybrid Coronary Approach for Optimal Revascularization: JACC Review Topic of the Week. J Am Coll Cardiol. 2020 Jul 21;76(3):321-333. doi: 10.1016/j.jacc.2020.04.078. PMID: 32674795.
17. Cook CM, Warisawa T, Howard JP, Keeble TR, Iglesias JF, et al. Algorithmic Versus Expert Human Interpretation of Instantaneous Wave-Free Ratio Coronary Pressure-Wire Pull Back Data. JACC Cardiovasc Interv. 2019 Jul 22;12(14):1315-1324. doi: 10.1016/j.jcin.2019.05.025. PMID: 31320025; PMCID: PMC6645043.
18. Petraco R, Bahl R, Almeida G, Bandeira D, Seligman H, et al. Can AI Capture and Quantify Clinical Expertise? Implications for Intracoronary Imaging in Percutaneous Coronary Intervention. J Soc Cardiovasc Angiogr Interv. 2025 Mar 18;4(3Part B):102523. doi: 10.1016/j.jscai.2024.102523. PMID: 40230670; PMCID: PMC11993851.
19. Samant S, Panagopoulos AN, Wu W, Zhao S, Chatzizisis YS. Artificial Intelligence in Coronary Artery Interventions: Preprocedural Planning and Procedural Assistance. J Soc Cardiovasc Angiogr Interv. 2025 Mar 18;4(3Part B):102519. doi: 10.1016/j.jscai.2024.102519. PMID: 40230668; PMCID: PMC11993872.
20. Khokhar AA, Marrone A, Bermpeis K, Wyffels E, Tamargo M, Fernandez-Avilez F, Ruggiero R, Złahoda-Huzior A, Giannini F, Zelias A, Madder R, Dudek D, Beyar R. Latest Developments in Robotic Percutaneous Coronary Interventions. Interv Cardiol. 2023 Dec 6;18:e30. doi: 10.15420/icr.2023.03. PMID: 38213745; PMCID: PMC10782427.
21. Biondi-Zoccai G, D'Ascenzo F, Giordano S, Mirzoyev U, Erol Ç, et al. Artificial Intelligence in Cardiology: General Perspectives and Focus on Interventional Cardiology. Anatol J Cardiol. 2025 Apr;29(4):152-163. doi: 10.14744/AnatolJCardiol.2025.5237. PMID: 40151850; PMCID: PMC11965948.
22. Łajczak P, Eltawansy S, Obi O, Sahin OK, Ayesha A, Almendral J, Selan J, Apolito R, Elashery A, Łajczak A, Buczkowski S, Jóźwik K, Nowakowski P, Janiec J, Żerdziński K, Schincariol M. Robotic percutaneous coronary intervention and the clinical effectiveness debate: Is newer always better? A systematic review and frequentist network meta-analysis. Cardiovasc Revasc Med. 2025 Jul;76:113-120. doi: 10.1016/j.carrev.2025.04.005. Epub 2025 Apr 3. PMID: 40253223.